DUALITYBIO-B

DualityBio-B surged 5.5% to HK$198.9 in the morning session after DB-1311 received breakthrough therapy designation. UBS initiated coverage with a Buy rating and TP of HK$320. Q4 operating loss widened 84.34% YoY due to R&D expansion, but net loss narrowed 28.06%. The stock remains 64.7% below its 52-week high of HK$563.5, yet trades above the 20-day MA of HK$190.86, with YTD decline of 32.89%. However, it had plunged 14% last week amid sector rotation.

Duality Biologics (9606.HK) staged a morning session rebound after opening lower, marking an intraday low of HK$182.5 before surging to close at HK$197.6, up 5.29% from the previous close of HK$187.7, driven by UBS initiating coverage with a Buy rating and a price target of HK$320, implying ~62% upside from the current price, alongside the company's core ADC drug DB-1311 receiving a breakthrough therapy designation from China's drug regulator. The stock subsequently hit the session high of HK$197.6, yet it still trades 64.93% below the 52-week high of HK$563.5 and has posted a YTD decline of 33.33%, with the 20-day MA (HK$194.35) and 60-day MA (HK$199.64) converging, indicating near-term tug-of-war. Financially, Q4 2025 revenue dropped 30.85% YoY to HK$346.3 million, while net loss narrowed 28.06% to HK$290.0 million, with EPS improving 93.51% YoY to -HK$3.269, offering marginal support as loss contraction aids valuation; however, the PB ratio of 6.68x and PE of -6.25x reflect persistent pre-profitability pressure.

Duality Biologics opened higher and rallied in the morning session, last trading at HKD 196.1 as of 10:02 BJ time, up 8.05%, primarily driven by UBS initiating coverage with a Buy rating and a HKD 320 target price. The stock hit an intraday high of HKD 196.3 and a low of HKD 188.0, forming a range of about HKD 8.3, yet remains below its 20-day MA of HKD 196.6 and 60-day MA of HKD 200.2. Year-to-date, it has declined 33.84%, and sits 65.2% below its 52-week high of HKD 563.5, indicating a weak price position. In Q4 2025, revenue fell 30.85% YoY to HKD 346 million, while net loss narrowed 28.06% YoY to HKD 290 million, showing operational improvement. However, the stock had previously experienced sharp swings after the breakthrough therapy designation for DB-1311, and today's gain partly reflects a rebound from that volatility.

Duality Biologics opened lower and traded unilaterally downward in the morning session, falling 5.1% to HK$182.8, an intraday low, mainly driven by profit-taking after a recent rally fueled by DB-1311's breakthrough therapy designation. The stock now trades below both its 20-day (HK$203.97) and 60-day (HK$201.88) moving averages, with a YTD decline of 38.33%. Q4 revenue fell 30.85% YoY to HK$346.3 million, while net loss narrowed 28.06% to HK$289.7 million. UBS initiated coverage with a Buy rating and a HK$320 target price, though the stock remains 67.56% below its 52-week high of HK$563.5 and only 15.33% above the 52-week low of HK$158.5. Nonetheless, session turnover was low at HK$24.6 million, indicating thin participation.

Duality Biologics staged a morning session rally after a low open, bottoming at HK$189.20 before climbing steadily to close at HK$202.00, up 5.2%, primarily driven by the news that its DB-1311 (BNT324) received breakthrough therapy designation from China's CDE. The stock reached the intraday high of HK$201.80 within just 21 minutes of the low. However, the company remains loss-making, posting a net loss of HK$289.7 million in Q4 2025, though losses narrowed 28.06% YoY, while operating losses widened 84.34% YoY to HK$320.4 million. Price-wise, the stock is still 64.15% below its 52-week high of HK$563.50, trading below its 20-day MA of HK$207.34, with a YTD decline of 31.85%.